KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Total Debt (2016 - 2025)

Historic Total Debt for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $50.4 million.

  • Inovio Pharmaceuticals' Total Debt changed N/A to $50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.4 million, marking a year-over-year change of. This contributed to the annual value of $13.3 million for FY2024, which is 2096.2% down from last year.
  • As of Q3 2025, Inovio Pharmaceuticals' Total Debt stood at $50.4 million.
  • Over the past 5 years, Inovio Pharmaceuticals' Total Debt peaked at $50.4 million during Q3 2025, and registered a low of $491645.0 during Q3 2021.
  • For the 5-year period, Inovio Pharmaceuticals' Total Debt averaged around $10.6 million, with its median value being $9.5 million (2025).
  • In the last 5 years, Inovio Pharmaceuticals' Total Debt crashed by 3815.23% in 2021 and then surged by 114810.85% in 2023.
  • Quarter analysis of 5 years shows Inovio Pharmaceuticals' Total Debt stood at $548032.0 in 2021, then skyrocketed by 198.12% to $1.6 million in 2022, then surged by 926.49% to $16.8 million in 2023, then fell by 20.96% to $13.3 million in 2024, then skyrocketed by 280.11% to $50.4 million in 2025.
  • Its Total Debt stands at $50.4 million for Q3 2025, versus $11.4 million for Q2 2025 and $9.5 million for Q1 2025.